Trials / Completed
CompletedNCT00499629
Study Evaluating the Safety of FXR-450 in Healthy Subjects
Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of FXR-450 Administered Orally to Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose of the study is to evaluate the safety of FXR-450 in healthy subjects. This study will also evaluate pharmacokinetics (PK) of FXR-450 in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FXR 450 | capsule, single oral doses from 10 mg to 450 mg |
| DRUG | placebo | capsule similar to active drug |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2008-02-01
- Completion
- 2008-02-01
- First posted
- 2007-07-11
- Last updated
- 2008-03-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00499629. Inclusion in this directory is not an endorsement.